Abstract 1273P
Background
ctDNA-based molecular residual disease (MRD) detection of postoperative plasma enables refining risk stratification to guide treatment precisely. The clinical efficacy of MNavigator V1 utilizing fixed panel detection scheme has been confirmed and published. Here, we reported its V2 improved version performance.
Methods
MNavigator V2 strategy combines the advantages of two classic technologies, WES-based personalized and non-customized off-the-shelf assay. In this assay, tissue somatic mutations were identified by CGP-sequencing with a 2.3 Mb 1021-gene panel, and then the top-ranked 20 mutations were selected. Tissue-specific customized panel combined with a lung universal core panel to monitor MRD by sequencing depth > 100,000x. The core panel can detect de novo mutations in ctDNA, especially targeted treatment-resistant mutations. Analytical validation was performed on a commercial MRD reference standard set, with VAF down to 0.005%. The retrospective cohort included 33 NSCLC patients (pts) treated with definitive surgery. Head-to-head compared MRD detection of this assay with MNavigator V1 that uses a 338-gene panel with a sequencing depth of 30,000x.
Results
This assay demonstrated the sample-level LOD of 0.005% by monitoring 20 variants, with a specificity of 100%. 10,625 NSCLC 1021panel sequencing data indicates 99% of pts available monitor 2 mutations, achieving 97.3% analytical sensitivity at 0.02% VAF. In the cohort, MRD was detected in 14/15 relapsed pts by both assays, apart from a brain-only metastasis pt. Recurrence-free pts with 2 years of follow-up were MRD-negative, yielding a specificity of 100% (18/18). MRD-detectable population was associated with a worse prognosis (HR=35.4). MNavigator V2 predicted relapse with a lead time of 143 days, 15 days ahead of V1. This may be related to more traced mutations (average 10 vs 5) and deeper sequencing depth, improving the capability to detect minimal tumor DNA residuals.
Conclusions
The CGP-based personalized MRD assay showed high analytical performance, and clinical assessment indicated superior sensitivity than fixed panel assays, providing greater potential for clinical benefit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
W. Gao.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
447P - Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis
Presenter: Lixi Li
Session: Poster session 04
448P - Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
Presenter: Hossameldin Abdallah
Session: Poster session 04
449P - Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
Presenter: Claudia von Arx
Session: Poster session 04
450P - A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2-negative advanced breast cancer
Presenter: Ying Zhang
Session: Poster session 04
451P - Breast Cancer Lighthouse study: 1 year follow-up results of ribociclib treatment patterns and clinical outcomes in a real-world Portuguese cohort
Presenter: Beatriz Gosalbez Pequeno
Session: Poster session 04
452P - A phase II trial of anlotinib and fulvestrant in patients with metastatic breast cancer previously treated with an aromatase inhibitor
Presenter: Xiaojia Wang
Session: Poster session 04
453P - Clinical outcomes of pyrotinib-based therapy after prior trastuzumab and pertuzumab in HER2-positive metastatic breast cancer
Presenter: Jinmei Zhou
Session: Poster session 04
454P - Real-world genomic profiling of patients with advanced or metastatic triple-negative breast cancer in the UK and EU4: A systematic literature review
Presenter: Barinder Singh
Session: Poster session 04
455P - Post progression treatments after endocrine therapy (ET) plus palbociclib in patients with HR+/HER2- metastatic breast cancer (MBC): A prospective, real-world study
Presenter: Raffaella Palumbo
Session: Poster session 04